RRPV BoNT-NMJ
Health and Human Services, Department of · OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE
This notice is not accepting responses (deadline was May 10, 2026, 8:00 PM EDT).
Page kept for research and related open opportunities below. For current work in this category, use the related notices or browse hubs.
- Response deadline
- May 10, 2026, 8:00 PM EDT
- Posted
- Apr 19, 2026
- Solicitation
- SSN-BARDA-04202026
- Set-aside
- None listed
- Place of performance
- Washington, DC, USA
- Contracting office
- BARDA - ASPR / DAAPPO / BARDA DCMA · WASHINGTON · DC
- Source
- SAM.gov · updated May 9, 2026
Description
Botulinum neurotoxins (BoNT/A�G) inhibit acetylcholine release at the neuromuscular junction through cleavage of SNARE proteins (e.g., SNAP-25, VAMP, syntaxin). Currently, BoNT characterization, including toxin potency and neutralization by medical countermeasures, is measured using mouse-based bioassays, primarily the Mouse Potency Assay (MPA) and Mouse Neutralization Assay (MNA), respectively. There is increasing scientific, ethical, and regulatory interest in transitioning to human-relevant in vitro systems that can provide mechanistic insight while reducing reliance on animal testing. NMJ micro-physiological systems may provide a biologically relevant platform capable of measuring BoNT potency and evaluating countermeasure efficacy. BARDA is interested in understanding whether NMJ-based in vitro platforms could support future development of validated assays capable of reducing and potentially replacing reliance on mouse bioassays for BoNT potency and neutralization measurements, with specific interest in systems that can show recovery of neuronal signaling and thereby be appropriate for medical countermeasures evaluation.
What similar awards have paid
Real federal awards already on the books in a similar lane — so you can size the opportunity, not guess. This is public history, not a bid price, cost estimate, or prediction that you will win.
Typical award size
$130,163
Middle of the pack for similar past awards
Most similar awards fall between $21,360 and $14.05M
Who has won work like this
Public awardees in this lane — useful for competitor scan or teaming ideas, not a ranked list of “best” firms.
- 1PARATEK PHARMACEUTICALS, INC1 award$265.32M
- 2MAPP BIOPHARMACEUTICAL, INC.2 awards$201.20M
- 3GLAXOSMITHKLINE, LLC11 awards$95.95M
- 4VENATORX PHARMACEUTICALS INC1 award$72.14M
- 5SELUX DIAGNOSTICS, INC.1 award$62.63M
- 6BECTON, DICKINSON AND COMPANY1 award$33.79M
- 7CERUS CORPORATION1 award$32.12M
- 8SEQIRUS INC1 award$2.80M
Recent examples
A few of the newest similar awards in our index.
- SEQIRUS INCSep 30, 2025Department of Health and Human Services$2.80MSource
- ARVYS PROTEINS, INC.Sep 24, 2025Department of Health and Human Services$4,300Source
- AMPSEQ LLCSep 23, 2025Department of Health and Human Services$24,200Source
- EMD MILLIPORE CORPSep 10, 2025Department of Health and Human Services$20,826Source
- BIOSKRYB GENOMICS, INC.Sep 9, 2025Department of Health and Human Services$23,807Source
- NOVOGENE CORPORATION INCSep 9, 2025Department of Health and Human Services$11,350Source
Drawn from official USAspending contract records in our index. Always confirm requirements on the SAM.gov notice before you bid.
Intelligence only — not legal advice or a guarantee of award. Always verify requirements on the official SAM.gov notice. Past award amounts are public history, not a suggested bid or prediction. Notice ID 78111dd8f1d54f3783a4e98804f52351.